11 June 2023: Clinical Research
Evaluating the One-Year Efficacy of Combined Anti-VEGF and Dexamethasone Implant Treatment for Macular Edema in Retinal Vein Occlusions
Fengmei Ren 1B* , Hui Gong 1D* , Han Zhang 1D* , Xiaoguang Zhang 1E , Xiaolin Liu 1F , Peifeng Gao 1D , Junying Li 2G* , Guisen Zhang 1AE*DOI: 10.12659/MSM.939277
Med Sci Monit 2023; 29:e939277
Table 1 Characteristics of all included subjects.
| Variables | Characteristics |
|---|---|
| Age (years) | 55.12±6.28 |
| Male (%)/female (%) | 15(44.1)/19(55.9) |
| CRVO (%) | 17 (50.0) |
| BRVO (%) | 17 (50.0) |
| Medical history | |
| With diabetes (%) | 14 (41.2) |
| With hypertension (%) | 3 (8.8) |
| With ischemia (%) | 11 (32.4) |
| Without ischemia (%) | 23 (67.6) |
| Baseline BCVA (LogMar) | 0.31±0.22 |
| Baseline IOP (mmHg) | 16.03±2.67 |
| Baseline CRT (μm) | 650.03±180.56 |
| Baseline SCP | 45.34±4.94 |
| Baseline DCP | 44.52±4.47 |
| FAZ area (mm) | 0.32±0.22 |
| FAZ circumference (mm) | 2.17±0.73 |
| Number of injections (n) | 3.15±1.02 |
| FAZ – foveal avascular zone; CRT – central retinal thickness; SCP – superficial capillary plexus; DCP – deep capillary plexus; IOP – intraocular pressure; BCVA – best corrected visual acuity. | |